Abstract
GnRH agonists are the established treatment of precocious puberty caused by premature stimulation of gonadotropin secretion. It has been reported that after an initial stimulation (“flare-up”) they reduce LH secretion by desensitization of pituitary GnRH receptors. Little has been published about the use of GnRH antagonists such as cetrorelix to control the onset of puberty and whether they are potentially advantageous compared with GnRH agonists. We conducted two multigroup experiments (12 and 10 d, respectively) treating prepubertal/peripubertal female rats with either the GnRH agonist triptorelin or buserelin and compared them with rats treated with the GnRH antagonist cetrorelix and controls to assess the effects on pubertal progress and serum hormones. In the second experiment, the effects of buserelin and cetrorelix on gene expression of the GnRH receptor, LH-β, FSH-β, and the alpha subunit genes in the pituitary were also investigated. Cetrorelix, triptorelin, and buserelin retarded the onset of puberty as determined by delayed vaginal opening, lower ovarian weights, and lower serum estradiol levels. However, although LH and FSH levels were stimulated by both agonists, they were inhibited by cetrorelix. In the cetrorelix versus buserelin experiment, pituitary gene expression of the GnRH receptor and LH-β subunit were significantly lower in cetrorelix treated rats compared with controls whereas buserelin had little effect. Expression of FSH-β and alpha subunit were stimulated by buserelin but not by cetrorelix. Even though all three of these GnRH analogues inhibited gonadal development and delayed the onset of puberty , the GnRH agonists had stimulating and inhibiting effects on the pituitary-gonadal axis whereas cetrorelix exerted only inhibiting effects. We conclude from this female rat model that cetrorelix may offer advantages for a more controlled medical treatment of precocious puberty compared with GnRH agonist treatment.
Similar content being viewed by others
Main
Onset of puberty is dependent on pulsatile release of hypothalamic GnRH from GnRH neurons (1). Premature release of GnRH causes central precocious puberty. GnRH agonists such as TRIP and BUS are the established treatment of central precocious puberty (2–4). Treatment with GnRH agonists causes an initial stimulation of the LH secretion (“flare-up”), which is followed by a low prepubertal LH secretion due to desensitization and/or down-regulation of pituitary GnRH receptors (4, 5). This method of treatment, however, is not without risks and side effects. Regular injections of these long-acting GnRH agonists are necessary to avoid a reactivation of the gonadotropin and gonadal steroid hormone secretion that occurs soon after treatment is discontinued (2).
Depending on the nature of the substitutions, synthetic GnRH analogues have either GnRH agonistic or GnRH antagonistic properties. The GnRH agonist TRIP (D-Trp6)-GnRH differs from the native peptide in position 6, the GnRH agonist BUS (D-Ser(tBu)6-NHEt10)-GnRH differs in positions 6 and 10, whereas the GnRH antagonist CET acetate (Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Pal3,D-Cit6,D-Ala10)-GnRH contains substitutions in positions 1,2, 3, 6, and 10 (6). CET is now in phase III clinical studies (7, 8) for suppression of gonadotropins and gonadal hormones in men and women and has been widely used for endocrine applications such as in vitro fertilization, influencing lipoprotein subclasses, and treatment of prostate cancer and benign prostate hyperplasia (7, 9–13). CET has a strong inhibitory action on hormone release and has a low frequency of side effects compared with other antagonists for which anaphylactoid reactions due to histamine release and immunosuppressive effects have been reported (14–16).
Little has been reported about the use of CET in controlling the onset of puberty and whether this GnRH antagonist offers advantages for regulating pituitary hormone secretion compared with GnRH agonists. Therefore, we treated prepubertal female rats with CET or GnRH agonists to investigate the effects on pubertal development, serum hormone levels, and the gene expression of GnRH receptor, LH-β, FSH-β, and the alpha subunit in the pituitary.
METHODS
Animals, drugs, and serum hormones.
Female Sprague Dawley rats were housed under standardized conditions (lights on 12 h from 0700 h to 1900 h, 25°C room temperature, 10 animals per cage). After randomization, in each cage were animals from all treatment groups. They had free access to water and were fed ad libitum. The doses of BUS, TRIP, and CET used have been shown to be effective in suppressing the gonadal hormones in previous experiments with rats (17, 18). In both experiments drugs were diluted with NaCl 0.9% to a volume of 0.4 mL for each injection. All animals were monitored for changes of the external and internal genitalia. Vaginal opening marked the first estrous cycle and the beginning of puberty (in controls at postnatal d 33–38). The studies were approved by the local ethical committee for animal experiments at the University of Göttingen.
Experiment 1—CET versus TRIP: Animals were randomized in five groups, each consisting of 12–16 animals. From d 25 to d 36 (12 d) rats were intraperitoneally injected once per day at 1800 h with either 1 × 0.4 mL NaCl 0.9% (placebo group), 1 × 100 μg or 1 × 10 μg CET (CET 100 or CET 10 group) or 1 × 100 μg or 1 × 10 μg TRIP (TRIP 100 or TRIP 10 group). Serum gonadotropins were measured at four different time points during treatment: 14 h after first injection; 24 h after third injection; 2 h after ninth injection; 14 h after last injection of drugs after decapitation in the morning. The first three blood samples were obtained by cannulation of the tail artery in slight ether narcosis and the fourth blood sample was collected from the trunk immediately after decapitation at d 37.
Experiment 2—CET versus BUS: Three groups consisting of 38–41 animals per group were formed by randomization. From d 28 to d 37 (10 d) rats were intraperitoneally injected with either 2 × 0.4 mL NaCl 0.9% daily at 0700 h (placebo group), 1 × 100 μg CET daily at 0700 h or 2 × 30 μg BUS daily at 0700 h and 1800 h. On d 37, rats of all three groups were decapitated 2 h after the last injection in the morning. Trunk blood was collected for measuring serum hormone levels and anterior pituitaries were rapidly removed and frozen on dry ice for mRNA studies.
Serum levels of LH, FSH, and estradiol levels were determined using established RIA methods. The antibodies were NIADDK rat–S7 (LH) and NIADDK rat–S11 (FSH); estradiol was measured by using a sensitive RIA (Diagnostic Systems Laboratories) with a lower detection limit of 6 pg/mL. Reference preparations were RP2 for both LH and FSH. For iodination, LH I-6 and FSH I-7 were used. To achieve maximum sensitivity 100 μL serum was used for LH and FSH measurements. Each assay was performed with freshly prepared tracer that had been purified by fast protein liquid chromatography-column chromatography on Superdex 75 column (Amersham Pharmacia Biotech, Freiburg, Germany). In pilot experiments, fractions were tested for maximum sensitivity. Based on these data, an elution pattern of the chromatography with regard to the fraction containing the optimal tracer was established. Under these conditions sensitivity limits of 0.1 ng/mL (LH) and 0.4 ng/mL (FSH) were achieved. The intra-and interassay coefficients of variation from replicates of pooled samples from ovariectomized rats were 7.5% and 11.5% (LH) and 8.5% and 13.5% (FSH).
RNA-preparation and competitive RT-PCR.
For generation of mutant RNA templates, composite primers were designed for each probe according to the method of Kephart (Promega Notes 68). These composite primers consist of the normal upstream or downstream primer sequence and a 15-bp sequence region located up to 100 nucleotides downstream in the RNA. An RT-PCR reaction was carried out with composite primer plus the respective sense or antisense primer and the resulting PCR products were cloned using the TOPO™ TA cloning kit® (Invitrogen, Groningen, The Netherlands). After sequencing, the RNA was reverse transcribed with the Reverse Transcription System® purchased from Promega. The isolation of total RNA from individual anterior pituitaries from animals in the second experiment was carried out with the RNeasy™ Total RNA Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. RNA concentrations were measured using the RiboGreen™ RNA quantitation reagent (Molecular Probes, Eugene, Oregon, U.S.A.). RT-PCR was conducted using SUPERSCRIPT™ for RT and SUPERMIX® for PCR (both purchased from GIBCO-BRL, Eggenstein, Germany). The RT reaction was carried out with 150 ng total RNA. Before RT-PCR reaction, various amounts of mutant RNA were added to all reaction vials. The concentration of this cRNA was evaluated for each investigated gene by pilot titration experiments using 150 ng native RNA co-reverse transcribed and subsequently co-amplified with a serial dilution of the corresponding mutant cRNA as previously described (19). For PCR reaction, 1–3 μL cDNA and 25 pM primer were added to the SUPERMIX solution. Table 1 shows primer pairs and numbers of cycles used for RT-PCR of native mRNA (20–23). The amplified PCR products were size-fractionated by electrophoresis in a 1.5% agarose gel in tris borate ethylene diamine tetracetic acid buffer and photographed after staining with ethidium bromide. Intensities of bands were evaluated with the Kodak DC 1D program.
Statistical evaluation and mathematical calculations.
Unless otherwise stated, results are presented as mean ± SEM. All data from the RIA and PCR analysis were statistically evaluated with one-way ANOVA followed by Dunnet's multiple t test using the Prism® program (GraphPad Software, Inc. San Diego, CA, U.S.A.). In case of nonparametric distribution (serum gonadotropins), the statistical analysis was performed for each of the four time points separately on the significance level alpha = 0.05 by using SAS 6.12 for Windows (SAS-Institute, Cary, NC, U.S.A.). The exact Kruskal-Wallis test was used to compare multiple groups, whereas the exact Mann-Whitney test was used for comparisons in pairs. Differences were considered significant if p < 0.05.
RESULTS
Pubertal development, weights and serum hormones.
In both experiments all treated animals appeared to be healthy. The body weight gain and the weights at d 37 were similar for all groups of both studies. Pubertal development was inhibited by all three GnRH analogues, as determined by lower percentage of vaginal opening at pubertal age versus controls (Fig. 1, a and b). Efficiency of treatment was confirmed by the significant reduction of ovarian and uterine weights (Fig. 2, a–c).
In the first experiment, after the first injection of CET 100 μg, serum LH levels were significantly lower in CET-treated rats, whereas in TRIP-treated rats significantly higher LH levels were found. Suppression of LH by CET and stimulation of LH release by TRIP was observed during the entire treatment (Table 2a). FSH levels were significantly lower under CET treatment and significantly higher after TRIP treatment compared with controls. FSH was more stimulated by TRIP 10 μg/d than by TRIP 100 μg/d (Table 2b). In the second experiment, estradiol levels were significantly lower in both CET and BUS treated rats (Fig. 3a). Two hours after the last injection, serum LH levels were again suppressed by CET and stimulated by the agonist BUS (Fig. 3b). FSH levels showed no significant change after CET treatment but were significantly higher after BUS treatment compared with controls (Fig. 3c).
Gene expression of pituitary GnRH receptor and gonadotropinsubunits.
In experiment 2 (CET versus BUS), treatment with CET caused a significant reduction of the gene expression of the GnRH receptor in the pituitary. In contrast, in BUS-treated rats the amount of GnRH receptor mRNA was slightly though not significantly higher than in the control group (Fig. 4). Likewise, expression of gonadotropin subunit LH-β was lowered by CET whereas there was no effect in BUS-treated rats. FSH-β expression and alpha subunit expression were significantly stimulated by BUS, but CET treatment did not change the mRNA levels of either hormone subunits (Fig. 5).
DISCUSSION
To our knowledge this is the first study in which the inhibitory effect of the GnRH antagonist CET on sexual maturation and on pituitary gene expression has been compared with the effects of the GnRH agonists TRIP and BUS. Our results demonstrate that each of the three GnRH analogues retards pubertal and gonadal development as indicated by a lower percentage of vaginal opening at pubertal age and, in particular, by lower ovarian weights and reduced estradiol levels. Even after shortening the treatment period, as in experiment 2, a profound inhibition of pubertal development was observed.
In CET-treated rats the serum LH and FSH levels were reduced, whereas during and after treatment with BUS or TRIP the serum LH and FSH levels were elevated. Nevertheless, retarded onset of pubertal development, lower ovarian and uterine weights, and lower estradiol levels were observed in the present study, implying that each GnRH analogue in effect inhibits the release of bioactive gonadotropins. The most likely explanation for this observation is that CET directly inhibits pituitary gonadotropin secretion whereas BUS and TRIP may cause intrinsic release of bioinactive gonadotropins. Supporting this idea are reports that in humans BUS releases bioinactive LH molecules into the circulation that are detected by RIA using polyclonal antibodies but not by immunoassays based on monoclonal antibodies (24, 25). This hypothesis of bioinactive LH release caused by GnRH agonists is supported by the observation that sera from women under BUS treatment do not stimulate testosterone production in the mouse interstitial cell in vitro bioassay (26). An alternative explanation for the elevated GnRH agonist-caused gonadotropin levels is that TRIP and BUS may cause a transient flare-up. To assess this phenomenon we collected blood samples at different time intervals (2 h, 14 h, and 24 h) after treatment. Our observations in this study contradicted the transient factor in the flare-up explanation. We consistently found significantly elevated LH and FSH concentrations in samplings up to 24 h after treatment. Similarly, in another study a 12-d treatment of male rats with BUS led to reduced testes size and lower serum testosterone but unchanged LH levels 24 h after the last injection (27). We postulate that after pretreatment with TRIP and BUS our RIA detected bioinactive rather than biologically active LH molecules, however further studies are needed to fully delineate the mechanisms of the GnRH analogues.
The low estradiol levels found in this study may be due to the lowered gonadotropin levels (in the case of CET) or, as discussed above, could also be the consequence of release of bioinactive LH (in the cases of TRIP and BUS) and/or a direct action of GnRH-analogues in the ovary. In fact, GnRH and its agonists are known to directly affect steroid production and proliferation of human and rat granulosa cells via specific GnRH receptors (28–30). Furthermore, the human and rat ovary have been found to express GnRH, suggesting that the peptide may be involved in regulating the endocrine function of the ovary (31–33). Recent data also indicate that CET reduces proliferation of granulosa cells more potently than BUS (34). Thus the possibility cannot be ruled out that CET reduces estradiol secretion not only by inhibiting LH release but also by directly reducing estradiol secretion via an ovarian mechanism. On the other hand, it may be possible that CET acts as an inhibitor of both the pituitary and ovary whereas agonists may not reduce gonadotropin release but directly act in the ovary.
To assess these putative divergent effects of CET versus BUS on the pituitary, we performed a second experiment with the focus on expression of relevant target genes in the pituitary. Only CET induced lower pituitary LH-β gene expression that corresponded with lower LH serum levels. BUS stimulated LH and FSH levels along with elevated gene expression of the alpha-subunit and FSH-β and slightly, but not significantly, increased amounts of LH-β-subunit mRNA. It should be emphasized that these observations were made 2 h after the last injection of the 10-d treatment.
Therapy of precocious puberty aims to prevent the action of untimely released endogenous GnRH by blocking the primary target, i.e. the pituitary, ideally causing a reduction of GnRH receptor gene expression and lower LH secretion because of “down-regulation” of the GnRH receptor. In our experiments with female peripubertal rats, only CET met both criteria, i.e. it inhibited GnRH receptor–mRNA levels in the pituitary and reduced gonadotropin levels in the serum. In a previous study with adult male rats it has been shown that CET decreased the number of GnRH receptor binding sites along with reduced GnRH receptor gene expression (35). It appears that CET prevents the binding of endogenous GnRH to its receptor without appreciable intrinsic effect on LH biosynthesis and release.
Further support for the lack of intrinsic effects of CET comes from a clinical study on normal men. In this study, after an initial high loading dose of CET, a lower daily maintenance dose was sufficient for suppression of LH, FSH, and testosterone (9). This reduction of the therapeutically efficient drug doses compared with the required continuation of regular injections of GnRH agonists to avoid reactivation of the gonadotropin and gonadal steroid hormone secretion may be advantageous in the use of CET versus agonists. It thus appears that GnRH antagonists may have two actions on the GnRH receptor: initially, and possibly most importantly, a competitive mechanism that prevents binding of endogenously released GnRH that is then followed by a down-regulation of pituitary GnRH receptors. This would explain the lower maintenance dose of the antagonists required for effective gonadotropin suppression.
This study shows that CET has only inhibiting effects on pituitary hormone secretion and gonadotropin subunit expression in peripubertal rats versus the stimulating as well as inhibiting effects observed for the GnRH agonists BUS and TRIP. Our data also suggest that CET affects pituitary LH release more specifically than BUS because of its parallel inhibition of transcription and secretion of LH. These more targeted effects coupled with CET's minimal side effects and lower maintenance dosage requirement would suggest that treatment of central precocious puberty is a potential clinical application for CET.
Abbreviations
- GnRH:
-
gonadotropin-releasing hormone
- CET:
-
cetrorelix
- TRIP:
-
triptorelin
- BUS:
-
buserelin
- RT-PCR:
-
reverse transcriptase polymerase chain reaction
References
Wildt L, Marshall G, Knobil E 1980 Experimental induction of puberty in the infantile female rhesus monkey. Science 207: 1373–1375
Oostdijk W, Partsch CJ, Drop SLS, Sippell WG 1991 Long-term results with a slow-release gonadotropin-releasing hormone agonist in central precocious puberty. Dutch-German Precocious Puberty Study Group. Acta Paediatr Scand Suppl 372: 39–45
Pescovitz OH, Barnes KM, Cutler GB Jr 1991 Effect of deslorelin dose in the treatment of central precocious puberty. J Clin Endocrinol Metab 72: 60–64
Sippell WG, Partsch CJ, Hümmelink R, Lorenzen F 1991 Long-term therapy with delayed-action LHRH-agonist decapeptyl depot in girls with precocious puberty. Gynäkologe 24: 108–113
Plosker GL, Brogden RN 1994 Leuprorelin—a review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs 48: 930–967
Haviv F, Bush EN, Knittle J, Greer J 1998 LHRH antagonists. Pharm Biotechnol 11: 131–149
Felberbaum R, Diedrich K 1996 Klinischer Einsatz der GnRH-Analoga im Rahmen der Sterilitätstherapie: Agonisten und Antagonisten. Gynäkologe 29: 420–432
Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, Devroey P 2000 Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the LH-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod 15: 526–531
Behre HM, Kliesch S, Pühse G, Reissmann T, Nieschlag E 1997 High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum LH, FSH, and testosterone in normal men. J Clin Endocrinol Metab 82: 1403–1408
Oliviennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R 1998 The use of GnRH antagonist (cetrorelix®) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod 13: 2411–2414
Eckardstein A, Kliesch S, Nieschlag E, Chirazi A, Assmann G, Behre HM 1997 Suppression of endogenous testosterone in young men increases serum levels of HDL subclass lipoprotein A-I and lipoprotein (a). J Clin Endocrinol Metab 82: 3367–3372
Lamharzi N, Schally AV, Koppan M 1998 LH-releasing hormone (LH-RH) antagonist cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Regul Pept 77: 185–192
Comaru-Schally AM, Brannan W, Schally AV, Colcolough M, Monga M 1998 Efficacy and safety of LH-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab 83: 3826–3831
Bokser L, Srkalovic G, Szepeshazi K, Schally AV 1991 Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of LH-releasing hormone (SB 75). Neuroendocrinology 54: 136–145
Morale MC, Batticane N, Bartoloni G, Guarcello V, Farinella Z, Galasso MG, Marchetti B 1991 Blockade of central and peripheral LH-releasing hormone (LHRH) receptors in neonatal rats with a potent LHRH-antagonist inhibits the morphofunctional development of the thymus and maturation of the cell-mediated and humeral immune responses. Endocrinology 128: 1073–1985
Phillips A, Hahn DW, Mc Guire JL, Ritchie D, Capetola RJ, Bowers C, Folkers K 1988 Evaluation of the anaphylactoid activity of a new LHRH antagonist. Life Sci 43: 883
Feleder C, Jarry H, Leonhardt S, Moguilevsky JA, Wuttke W 1996 Evidence to suggest that gonadotropin-releasing hormone inhibits its own secretion by affecting hypothalamic amino acid neurotransmitter release. Neuroendocrinology 64: 298–304
Halmos G, Schally AV, Pinski J, Vadillo-Buenfil M, Groot K 1996 Down-regulation of pituitary receptors for LH-releasing hormone (LH-RH) in rats by LH-RH antagonist cetrorelix. Proc Natl Acad Sci U S A 93: 2398–2402
Seong JY, Jarry H, Kuhnemuth S, Leonhardt S, Wuttke W, Kim K 1995 Effect of GABAergic compounds on gonadotropin-releasing hormone receptor gene expression in the rat. Endocrinology 136: 2587–2593
Kaiser UB, Zhao D, Cardona GR, Chin WW 1992 Isolation and characterization of cDNAs encoding the rat pituitary gonadotropin-releasing hormone receptor. Biochem Biophys Res Commun 189: 1645–1652
Chin WW, Godine JE, Klein DR, Chang AS, Tan LK, Habener JF 1983 Nucleotide sequence of the cDNA encoding the precursor of the beta subunit of rat lutropin. Proc Natl Acad Sci U S A 80: 4649–4653
Kato Y, Ezashi T, Hirai T, Kato T 1990 Strain difference in nucleotide sequences of rat glycoprotein hormone subunit cDNAs and gene fragment. Zool Sci 7: 879–887
Godine JE, Chin WW, Habener JF 1982 Alpha subunit of rat pituitary glycoprotein hormones. J Biol Chem 257: 8368–8371
Kwekkeboom DJ, Lamberts SW, Blom JH, Schroeder FH, De Jong FH 1990 Prolonged treatment with the GnRH analogue buserelin does not affect alpha-subunit production by the pituitary gonadotroph. Clin Endocrinol Oxf 32: 443–451
Uemura T, Yanagisawa T, Shirasu K, Matsuyama A, Minaguchi H 1992 Mechanisms involved in the pituitary desensitization induced by gonadotropin-releasing hormone agonists. Am J Obstet Gynecol 167: 283–291
Jaakkola T, Ding YQ, Kellokumpu-Lehtinen P, Valavaara R, Martikainen H, Tapanainen J 1990 The ratios of serum bioactive/immunoreactive LH and FSH in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay. J Clin Endocrinol Metab 70: 1496–1505
Huhtaniemi IT, Warren DD, Catt KJ 1983 Comparison of oestrogen and GnRH agonist analogue-induced inhibition of the pituitary-testicular function in rat. Acta Endocrinol Copenh 103: 163–171
Hori H, Uemura T, Minaguchi H 1998 Effects of GnRH on protein kinase C activity, Ca2+ mobilization and steroidogenesis of human granulosa cells. Endocr J 45: 175–182
Lin Y, Kahn JA, Hillensjo T 1999 Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?. Hum Reprod 14: 885
Mori H, Ohkawa T, Takada S, Morita T, Yago N, Arakawa S, Okinaga S 1994 Effects of gonadotropin-releasing hormone agonist on steroidogenesis in the rat ovary. Horm Res 41: 14
Saragueta PE, Lanuza GM, Baranao JL 1997 Inhibitory effect of gonadotrophin-releasing hormone (GnRH) on rat granulosa cell DNA synthesis. Mol Reprod Dev 47: 170–174
Uemura T, Namiki T, Kimura A, Yanagisawa T, Minaguchi H 1994 Direct effects of gonadotropin-releasing hormone on the ovary in rats and humans. Horm Res 41: 7
Kang SK, Choi KC, Cheng KW, Nathwani PS, Auersperg N, Leung PC 2000 Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium. Endocrinology 141: 72–80
Yano T, Yano N, Matsumi H, Morita Y, Tsutsumi O, Schally AV, Taketani Y 1997 Effect of LH-releasing hormone analogs on the rat ovarian follicle development. Horm Res 48: 35
Pinski J, Lamharzi N, Halmos G, Groot K, Jungwirth A, Vadillo-Buenfil M, Kakar SS, Schally AV 1996 Chronic administration of the LH-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor mRNA levels in rats. Endocrinology 137: 3430–3436
Acknowledgements
The authors thank Dr. Reissmann, ASTA Medica, Frankfurt, Germany, who kindly provided the drug cetrorelix acetate to us as a gift. We also thank M. Neff-Heinrich in editing this article, M. Metten for her kind support in the laboratory, and U. Munzel, Department of Medical Statistics, University of Göttingen, for statistical analysis of the data.
Author information
Authors and Affiliations
Additional information
Parts of the studies were supported by a DFG-grant (Ja 398 (6–1).This paper is part of the habilitation thesis of C. Roth.
Rights and permissions
About this article
Cite this article
Roth, C., Leonhardt, S., Seidel, C. et al. Comparative Analysis of Different Puberty Inhibiting Mechanisms of Two GnRH Agonists and the GnRH Antagonist Cetrorelix Using a Female Rat Model. Pediatr Res 48, 468–474 (2000). https://doi.org/10.1203/00006450-200010000-00009
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1203/00006450-200010000-00009
This article is cited by
-
The ovarian reserve is depleted during puberty in a hormonally driven process dependent on the pro-apoptotic protein BMF
Cell Death & Disease (2017)
-
Hypothalamic Suppression Decreases Bone Strength Before and After Puberty in a Rat Model
Calcified Tissue International (2009)
-
A dose-response study on the estrogenic activity of benzophenone-2 on various endpoints in the serum, pituitary and uterus of female rats
Archives of Toxicology (2006)